AbbVie today announced the completion of its acquisition of Cerevel Therapeutics (NASDAQ: CERE), making Cerevel a part of AbbVie. “AbbVie’s acquisition of Cerevel strengthens our foundation in neuroscience and positions…
Lilly announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg, or 15 mg) in adults…
BioNTech Announces Promising Phase 2 Results for mRNA Immunotherapy BNT111 in Advanced Melanoma BioNTech today revealed positive topline data from its ongoing Phase 2 clinical trial (EudraCT No.: 2020-002195-12; NCT04526899)…
WuXi AppTec Reports First Half 2024 Financial Results WuXi AppTec, a global leader in R&D and manufacturing services for the pharmaceutical and life sciences sectors, has announced its financial results…
Today, Eisai Co. Ltd. presented new findings on lecanemab-irmb (branded as LEQEMBI® in the U.S.) at the Alzheimer’s Association International Conference (AAIC) 2024 in Philadelphia and online. This dual-acting anti-amyloid…
Biogen, Beckman Coulter, and Fujirebio have announced a collaboration to identify and develop blood-based biomarkers for tau pathology in Alzheimer’s disease (AD). The goal is to create new tests that…
Vertex Announces FDA Acceptance of Suzetrigine NDA for Acute Pain Vertex Pharmaceuticals today revealed that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for…
The interim analysis of the AMPLIFY Phase III trial revealed promising results for AstraZeneca’s Calquence (acalabrutinib) combined with venetoclax, with or without obinutuzumab, in treating chronic lymphocytic leukaemia (CLL). The…
Novartis announced that the US Food and Drug Administration (FDA) has granted Priority Review status to Scemblix® (asciminib) for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive chronic…
Allergan Aesthetics is excited to announce the return of JUVÉDERM® Day on Wednesday, August 21. Following the success of its inaugural event, JUVÉDERM® Day offers limited-time deals, savings, and exclusive…
The European Commission (EC) has approved Vabysmo® (faricimab) for treating visual impairment caused by macular edema secondary to retinal vein occlusion (RVO), which includes branch RVO and central RVO. This…
Roche announced today the completion of its acquisition of LumiraDx’s Point-of-Care technology, following the necessary antitrust and regulatory approvals. The acquisition will see Roche integrate LumiraDx’s multi-assay point-of-care platform, along…